Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement ...

Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

This discovery not only unveils a novel mechanism by which BAT influences liver metabolism but also highlights miR-206-3p as ...

Researchers have mapped human fat tissue at single-cell resolution, uncovering how obesity alters cellular stress, ...

Results reveal that weight loss has significant effects on cellular processes that are known to affect metabolic health and ...

A GLP-1/glucagon dual agonist conferred weight loss of up to 12.55% at 32 weeks for adults with overweight or obesity, ...

We asked experts to explain how belly fat can cause pain.

Many people who have struggled with their weight have been told to “eat less and move more.” Others have spent years juggling ...

Although obese individuals are at greater risk of diabetes, high blood pressure or high cholesterol, not all obese people ...

Visceral adipose tissue and subcutaneous adipose tissue were quantified on abdominal MRI scans performed at two imaging visits.